UNC2881
CAS.NO: 1493764-08-1 Category: Vesicular stomatitis virus (VSV) Mol. Formula: C25H33N7O2 Mol. Wt.: 463.58
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Description: UNC2881 is a potent Mer kinase inhibitor. UNC2281 inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. Treatment with UNC2281 is also sufficient to block EGF-mediated stimulation of a chimeric receptor containing the intracellular domain of Mer fused to the extracellular domain of EGFR. In addition, UNC2881 potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathologic thrombosis.
| Synonyms | UNC2881;1493764-08-1;N-(4-(1H-Imidazol-1-yl)benzyl)-2-(butylamino)-4-(((1r,4r)-4-hydroxycyclohexyl)amino)pyrimidine-5-carboxamide;UNC 2881;CHEMBL3093756;2-(butylamino)-4-[(4-hydroxycyclohexyl)amino]-N-[(4-imidazol-1-ylphenyl)methyl]pyrimidine-5-carboxamide;N-(4-(1H-Imidazol-1-yl)benzyl)-2-(butylamino)-4-((trans-4-hydroxycyclohexyl)amino)pyrimidine-5-carboxamide;SCHEMBL16435501;SCHEMBL17167888;SCHEMBL25422930;HMS3653M12;HMS3747I07;BCP12436;EX-A2176;UNC-2881;UNC2881?;BDBM50444241;s7325;AKOS024464756;AKOS026750571;CCG-269383;CS-3255;NCGC00390386-01;NCGC00485937-01;AC-31424;AS-55931;BU167099;DA-44177;HY-15798;PD052365;UNC2881, >=98% (HPLC);SW220192-1;C72843;2-(butylamino)-4-[(4-hydroxycyclohexyl)amino]-N-{[4-(imidazol-1-yl)phenyl]methyl}pyrimidine-5-carboxamide;2-(butylamino)-N-{[4-(imidazol-1-yl)phenyl]methyl}-4-{[(1r,4r)-4-hydroxycyclohexyl]amino}pyrimidine-5-carboxamide;N-(4-(1H-imidazol-1-yl)benzyl)-2-(butylamino)-4-(((1s,4s)-4-hydroxycyclohexyl)amino)pyrimidine-5-carboxamide; |
| IUPAC Name | 2-(butylamino)-4-[(4-hydroxycyclohexyl)amino]-N-[(4-imidazol-1-ylphenyl)methyl]pyrimidine-5-carboxamide |
| SMILES | CCCCNC1=NC(N[C@H]2CC[C@H](O)CC2)=C(C(NCC3=CC=C(N4C=NC=C4)C=C3)=O)C=N1 |
| InChI | InChI=1S/C25H33N7O2/c1-2-3-12-27-25-29-16-22(23(31-25)30-19-6-10-21(33)11-7-19)24(34)28-15-18-4-8-20(9-5-18)32-14-13-26-17-32/h4-5,8-9,13-14,16-17,19,21,33H,2-3,6-7,10-12,15H2,1H3,(H,28,34)(H2,27,29,30,31) |
| InChI Key | NPVXOWLPOFYACO-UHFFFAOYSA-N |
| Density | 1.31±0.1 g/cm3(Predicted) |
| Appearance | Solid |
| Purity | 98% |
| Drug Resistance | Drug resistance mechanism: UNC2881 targets specific kinases that play a role in cell signaling pathways, potentially leading to resistance through gene amplification or mutation. Common mutations: Mutations in the ATP-binding site of kinases can reduce UNC2881's efficacy, causing resistance by preventing drug binding. Resistance-related sites: Alterations in the gatekeeper residue within the kinase domain may lead to resistance by sterically hindering UNC2881's access. Cross-resistance situations: Resistance to UNC2881 may confer cross-resistance to other kinase inhibitors targeting similar pathways. Monitoring suggestions: Regularly assess genetic mutations in target kinases to ensure effective use of UNC2881. |
| Applications | Antiviral Research: UNC2881 demonstrates potent antiviral properties, making it a valuable asset in the development of novel therapeutic strategies. Viral Inhibition Studies: Effective in inhibiting replication of various virus strains, offering significant potential for broad-spectrum antiviral applications. Drug Development: Serves as a lead compound in antiviral drug development, enhancing the pipeline for new antiviral medications. Molecular Mechanism Exploration: Facilitates the study of viral entry and replication processes, contributing to a deeper understanding of viral pathogenesis. Biotechnology Applications: Utilized in biotechnology for the development of antiviral agents, supporting innovative solutions in viral infection management. |
| Protocol Notes | Storage Conditions: Store UNC2881 at -20℃. Ensure that UNC2881 is kept in a tightly sealed container to maintain its stability and prevent degradation. Solution Preparation: Dissolve UNC2881 in DMSO. Prepare a stock solution by dissolving UNC2881 in dimethyl sulfoxide (DMSO) to achieve the desired concentration. Operation Precautions: Handle UNC2881 with care. Use appropriate personal protective equipment and handle within a fume hood to avoid exposure. Stability Monitoring: Check UNC2881 for color change. Regularly inspect the solution for any discoloration or precipitation which might indicate instability. Light Sensitivity: Protect UNC2881 from light. Store and handle in a dark environment to prevent photodegradation. |
| Drug Combination | Purpose of Combination: Enhancing therapeutic efficacy. Combining UNC2881 with other agents can potentiate its effects, leading to improved outcomes in research settings. Common Strategy: Synergistic agents. Researchers often combine UNC2881 with kinase inhibitors to explore potential synergistic effects and broaden therapeutic targets. Benefit: Reduced resistance risk. The combination can mitigate the risk of developing resistance, a common challenge in long-term studies. Precaution: Drug interactions. Careful consideration of potential interactions with co-administered compounds is essential to avoid confounding study results. Pharmacokinetic Consideration: Metabolic pathways. Understanding the metabolic pathways of UNC2881 and its partners is crucial for accurate data interpretation and experimental design. |
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors
Journal: Proceedings of the National Academy of Sciences of the United States of America
Date: 11/23/2020
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein
Journal: Molecular Pharmacology
Date: 11/1/2019
Methods of treating cancer using liposomal particles comprising anticancer agents and pharmaceutical compositions related thereto
Patent ID: WO2023122577A2
Still have questions?
